Grace Therapeutics, Inc GRCE

Healthcare

Grace Therapeutics, Inc., formerly Acasti Pharma Inc., is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its therapeutic pipeline consists of three clinical-stage drug candidates supported by an intellectual property portfolio of over 40 granted and pending patents in various jurisdictions. Its lead drug candidate, GTX-104, is a clinical-stage, novel, injectable formulation of nimodipine being developed for intravenous (IV) infusion in aneurysmal subarachnoid hemorrhage (aSAH) patients to address significant unmet medical needs. GTX-104 provides a convenient IV delivery of nimodipine in the intensive care unit, eliminating the need for nasogastric tube administration in unconscious or dysphagic patients. Its other pipeline drug candidates include GTX-102, which is an oral-mucosal betamethasone spray for the treatment of Ataxia Telangiectasia and GTX-101, which is a topical bio adhesive film-forming bupivacaine spray for Postherpetic Neuralgia.

NDAQ:GRCE - Post by User

Grace Therapeutics, Inc

Bullboard Posts

Comment by EternalPonzion Feb 10, 2020 3:13pm

126 Views

Post# 30669518

RE:RE:RE:Delay = More Financing = No one will touch it till then

It is unlikely that Acasti is footing the entire bill for this investigation. The CRO (IQVIA) will be also, most assuredly if they are at fault somehow. With FDA involved a pseudo approval process is underway now. Official approval will be a formality so to answer your question, yes the price will be bid up. Greed will ensure it, much as fear has forced it down.

Bullboard Posts

Barrick Gold employees detained in Mali amid ongoing dispute